Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy

Journal of Laboratory and Clinical Medicine

Volumn 141, Issue 2, 2003, Pages 121-130

  Obejero Paz, Carlos A ^a,b   Yang, Tianen ^a,b   Dong, Wei Qiang ^a,b   Levy, Matthew N ^a,b   Brittenham, Gary M ^a,b   Kuryshev, Yuri A ^a,b   Brown, Arthur M ^a,b,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c Rammelkamp Center for Education and Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; DEFEROXAMINE MESYLATE; IRON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CARDIOMYOPATHY; CONTROLLED STUDY; CYTOPLASM; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; ECG ABNORMALITY; ELECTROCARDIOGRAM; FEMALE; GERBIL; HEART FAILURE; HEART MUSCLE CELL; HEART VENTRICLE EXTRASYSTOLE; IRON OVERLOAD; LOW DRUG DOSE; NONHUMAN; PR INTERVAL; QRS COMPLEX; QT INTERVAL; RAT; ST SEGMENT; SURVIVAL; T WAVE;

EID: 0037323129     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1067/mlc.2003.18     Document Type: Article

References (44)

1. Bartfay WJ, Butany J, Lehotay DC, Sole MJ, Hou D, Bartfay E, et al. A biochemical, histochemical, and electron microscopic study on the effects of iron loading on the hearts of mice. Cardiovasc Pathol 1999;8:305-14.
2. Carthew P, Dorman BM, Edwards RE, Francis JE, Smith AG. A unique rodent model for both the cardiotoxic and hepatotoxic effects of prolonged iron overload. Lab Invest 1993;69:217-22.
3. Pechet GS. Parenteral iron overload: organ and cell distribution in rats. Lab Invest 1969;20:119-26.
4. Kuryshev YA, Brittenham GM, Fujioka H, Kannan P, Shieh CC, Cohen SA, et al. Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes: implications for the arrhythmogenesis of human siderotic heart disease. Circulation 1999;100:675-83.
5. Yang T, Dong W, Kuryshev Y, Obejero-Paz C, Levy M, Brittenham G, et al. Bimodal cardiac dysfunction in an animal model of iron-overload. J Lab Clin Med 2002;140:263-71.
6. Engle MA. Cardiac involvement in Cooley's anemia. Ann N Y Acad Sci 1964;119:694-702.
7. Ehlers KH, Levin AR, Markenson AL, Marcus JR, Klein AA, Hilgartner MW, et al. Longitudinal study of cardiac function in thalassemia major. Ann N Y Acad Sci 1980;344:397-404.
8. Nienhuis AW, Griffith P, Strawczynski H, Henry W, Borer J, Leon M, et al. Evaluation of cardiac function in patients with thalassemia major. Ann N Y Acad Sci 1980;344:384-96.
9. Jessup M, Manno CS. Diagnosis and management of iron-induced heart disease in Cooley's anemia. Ann N Y Acad Sci 1998;850:242-50.
10. Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R, et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 1985;312:1600-3.
11. Rahko PS, Salerni R, Uretsky BF. Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overload. J Am Coll Cardiol 1986;8:436-40.
12. Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Ward SE, Agnew JE, et al. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol 1990;84:113-7.
13. Ehlers KH, Giardina PJ, Lesser ML, Engle MA. Hilgartner MW. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. J Pediatr 1991;118:540-5.
14. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-73.
15. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000;95:1229-36.
16. Hershko C, Link G, Konijn AM, Huerta M, Rosenmann E, Reinus C. The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment. J Lab Clin Med 2002;139:50-8.
17. Borgna-Pignatti C, Cohen A. Evaluation of a new method of administration of the iron chelating agent deferoxamine. J Pediatr 1997;130:86-8.
18. Torrance JD, Bothwell TH. A simple technique for measuring storage iron concentrations in formalinised liver samples. S Afr J Med Sci 1968;33:9-11.
19. Overmoyer BA, McLaren CE, Brittenham GM. Uniformity of liver density and nonheme (storage) iron distribution. Arch Pathol Lab Med 1987;111:549-54.
20. Adolpf EF. Ranges of heart rates and their regulations at various ages (rat). Am J Psysiol 1967;212:595-602.
21. Lakatta EG. Cardiovascular system. In: Masoro EJ, editor. Handbook of physiology: section 11: aging. New York: Oxford University Press, 1995:425-7.
22. Kaye SB, Owen M. Cardiac arrhythmias in thalassaemia major: evaluation of chelation treatment using ambulatory monitoring. Br Med J 1978;1:342.
23. Buja LM, Roberts WC. Iron in the heart: etiology and clinical significance. Am J Med 1971;51:209-21.
24. Porter JB. Practical management of iron overload. Br J Haematol 2001;115:239-52.
25. Zanninelli G, Glickstein H, Breuer W, Milgram P, Brissot P, Hider RC et al. Chelation and mobilization of cellular iron by different classes of chelators. Mol Pharmacol 1997;51:842-52.
26. Rothman RJ, Serroni A, Farber JL. Cellular pool of transient ferric iron, chelatable by deferoxamine and distinct from ferritin, that is involved in oxidative cell injury. Mol Pharmacol 1992;42:703-10.
27. Staubli A, Boelsterli UA. The labile iron pool in hepatocytes: prooxidant-induced increase in free iron precedes oxidative cell injury. Am J Physiol 1998;274:G1031-7.
28. Roberts S, Bomford A. Ferritin iron kinetics and protein turnover in K562 cells. J Biol Chem 1988;263:19181-7.
29. Breuer W, Epsztejn S, Cabantchik ZI. Iron acquired from transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable iron(II). J Biol Chem 1995;270:24209-15.
30. Cable H, Lloyd JB. Cellular uptake and release of two contrasting iron chelators. J Pharm Pharmacol 1999;51:131-4.
31. Laub R, Schneider YJ, Octave JN, Trouet A, Crichton RR. Cellular pharmacology of deferrioxamine B and derivatives in cultured rat hepatocytes in relation to iron mobilization. Biochem Pharmacol 1985;34:1175-83.
32. Shiloh H, Iancu TC, Bauminger ER, Link G, Pinson A, Hershko C. Deferoxamine-induced iron mobilization and redistribution of myocardial iron in cultured rat heart cells: studies of the chelatable iron pool by electron microscopy and Mossbauer spectroscopy. J Lab Clin Med 1992;119:428-36.
33. Schellhammer PF, Engle MA, Hagstrom JW. Histochemical studies of the myocardium and conduction system in acquired iron-storage disease. Circulation 1967;35:631-7.
34. Vigorita VJ, Hutchins GM. Cardiac conduction system in hemochromatosis: clinical and pathologic features of six patients. Am J Cardiol 1979;44:418-23.
35. Fitchett DH, Coltart DJ, Littler WA, Leyland MJ, Trueman T, Gozzard DI, et al. Cardiac involvement in secondary haemochromatosis: a catheter biopsy study and analysis of myocardium. Cardiovasc Res 1980;14:719-24.
36. Engle MA, Erlanson M, Smith CH. Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation 1964;30:698-705.
37. James TN. Pathology of the cardiac conduction system in hemochromatosis. N Engl J Med 1964;271:92-4.
38. Kremastinos DT, Tiniakos G, Theodorakis GN, Katritsis DG, Toutouzas PK. Myocarditis in beta-thalassemia major: a cause of heart failure. Circulation 1995;91:66-71.
39. Chiang CE, Roden DM. The long QT syndromes: genetic basis and clinical implications. J Am Coll Cardiol 2000;36:1-12.
40. Cogswell ME, McDonnell SM, Khoury MJ, Franks AL, Burke W, Brittenham G. Iron overload, public health, and genetics: evaluating the evidence for hemochromatosis screening. Ann Intern Med 1998;1129:971-9.
41. Veglio F, Melchio R, Rabbia F, Molino P, Genova GC, Martini G, et al. Blood pressure and heart rate in young thalassemia major patients. Am J Hypertens 1998;11:539-47.
42. Bartfay WJ, Dawood F, Wen WH, Lehotay DC, Hou D, Bartfay E, et al. Cardiac function and cytotoxic aldehyde production in a murine model of chronic iron-overload. Cardiovasc Res 1999;43:892-900.
43. Lesnefsky EJ. Tissue iron overload and mechanisms of iron-catalyzed oxidative injury. Adv Exp Med Biol 1994;366:129-46.
44. Bartfay WJ, Bartfay E. Iron-overload cardiomyopathy: evidence for a free radical-mediated mechanism of injury and dysfunction in a murine model. Biol Res Nurs 2000;2:49-59.